Amelioration
of the development of chronic renal failure by systemic enzyme
treatment in the rat model of 5-6th nephrectomy
Sebeková K.1,
Paczek L.2, Dämmrich J.3, Ling H.3,
Schenk O.3, Gaciong Z.2, Spustová V.1,
Heidland A.3. Amelioration of the development of chronic
renal failure by systemic enzyme treatment in the rat model of 5/6
nephrectomy. Inter. Journal of Tissue Reactions 1997, Vol. XIX, No.
1/2, pp 97 - abstract
121, ISSN 0250-0868. 149K/245 (19-04-2)
1 Institute of Preventive and Clinical Medicine, Bratislava,
Slovakia. 2 Transplantation Institute, Warsaw, Poland. 3 University
of Wuerzburg, Germany.
7th Interscience World Conference on Inflammation, Antirheumatics,
Analgesics, Immunomodulators, 1997, May 19-21, Geneva, Switzerland.
We addressed the question whether systemic
administration of proteases may retard the progressive course of
chronic renal failure. The rat model of subtotal nephrectomy
(5/6-Nx) was used. Phlogenzym® (Mucos, Geretsried, Germany), a fixed
combination of trypsin, bromelin and rutosid was administered.
5/6-NX male Wistar rats were randomized into control (C, n=7, 2 ml
of .9 % NaCl/day i.p.) and test group (P, n=7, treated with 12 mg of
Phlogenzym in 2 ml of .9 % NaCl/day i.p.). After 6 weeks the
actively treated group showed lower mean plasma creatinine levels,
higher clearance of creatinine and lower proteinuria as compared to
placebo group. BUN level did not change. Renal morphology revealed
that the percentual volume fraction of interstitial tissue in renal
cortex, the number of infiltrating mononuclear cells and the amount
of collagen fibres was lower in the protease treated group.
Activities of lysosomal proteases (cathepsin L, B, and H), which are
decreased in the remnant kidney model, increased significantly in
the Phlogenzym treated group, both in isolated glomeruli and
tubules. Decreased formation of cytokines was reflected by the lower
urinary output of TGF-b1.
Conclusion
For the first time, evidence was given that protease treatment is
beneficial in a non-immune mediated renal disease. Phlogenzym
ameliorates the development of tubulo-interstitial fibrosis, and
progression of chronic renal failure in the model of 5/6
nephrectomised rats probably by diminishing the cytokine formation
in renal tissue and its release from infiltrating cells.
This study was also published in other journals, which have the following
reviews on this website::
Nieren-und Hochdruckkrankheiten, 1997, Jahrgang 26, Nr. 6, pp. 277 -
281; 345 KA (5-08-1)
Mineral and Electrolyte Metabol. 1997: 23, pp 291-295. 344 KA
(17-05-1)
(Full Text)